Moderate to Severe Atopic Dermatitis in Children: Focus on Systemic Th2 Cytokine Receptor Antagonists and Janus Kinase Inhibitors

Overview

Journal Clin Exp Pediatr

Specialty Pediatrics

Date 2023 Jun 15

PMID 37321570

Authors

Jeong Hee Kim

Mona Salem Samra

Affiliations

Soon will be listed here.

Abstract

Atopic dermatitis (AD) is a lifelong disease that markedly impairs quality of life. AD is considered a starting point of the "atopic march," which begins at a young age and may progress to systemic allergic diseases. Moreover, it is strongly associated with comorbid allergic and inflammatory diseases including arthritis and inflammatory bowel disease. Understanding the pathogenesis of AD is essential for the development of targeted therapies. Epidermal barrier dysfunction, immune deviation toward a T helper 2 proinflammatory profile, and microbiome dysbiosis play important roles via complex interactions. The systemic involvement of type 2 inflammation, wheather acute or chronic, and whether extrinsic or intrinsic, is evident in any type of AD. Studies on AD endotypes with unique biological mechanisms have been conducted according to clinical phenotypes, such as race or age, but the endotype for each phenotype, or endophenotype, has not yet been clearly identified. Therefore, AD is still being treated according to severity rather than endotype. Infancy-onset and severe AD are known risk factors leading to atopic march. In addition, up to 40% of adult AD are cases of infancy-onset AD that persist into adulthood, and these are often accompanied by other allergic diseases. Therefore, early intervention strategies to identify high-risk infants and young children, repair an impaired skin barrier, and control systemic inflamation may improve long-term outcomes in AD patients. However, to the best of our knowledge, no study has evaluated the effectiveness of early intervention on atopic march using systemic therapy in high-risk infants. This narrative review addresses the latest knowledge of systemic treatment, including Th2 cytokine receptor antagonists and Janus kinase inhibitors, for children with moderate to severe AD that is refractory to topical treatment.

References

Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L . Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. Dermatol Ther (Heidelb). 2022; 12(3):631-642. PMC: 8941010. DOI: 10.1007/s13555-021-00678-7. View

Esaki H, Brunner P, Renert-Yuval Y, Czarnowicki T, Huynh T, Tran G . Early-onset pediatric atopic dermatitis is T2 but also T17 polarized in skin. J Allergy Clin Immunol. 2016; 138(6):1639-1651. DOI: 10.1016/j.jaci.2016.07.013. View

Simpson E, Lacour J, Spelman L, Galimberti R, Eichenfield L, Bissonnette R . Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020; 183(2):242-255. DOI: 10.1111/bjd.18898. View

Alexander M, Luo Y, Raimondi G, OShea J, Gadina M . Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. Pharmaceuticals (Basel). 2022; 15(1). PMC: 8779366. DOI: 10.3390/ph15010048. View

Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y . Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2017; 73(1):29-36. DOI: 10.1111/all.13239. View

Simpson E, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J . Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023; 159(2):182-191. PMC: 9857439. DOI: 10.1001/jamadermatol.2022.5534. View

Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T . Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017; 66(3):398-403. DOI: 10.1016/j.alit.2016.12.002. View

Mold J, Venkatasubrahmanyam S, Burt T, Michaelsson J, Rivera J, Galkina S . Fetal and adult hematopoietic stem cells give rise to distinct T cell lineages in humans. Science. 2010; 330(6011):1695-9. PMC: 3276679. DOI: 10.1126/science.1196509. View

Cork M, Thaci D, Eichenfield L, Arkwright P, Hultsch T, Davis J . Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2019; 182(1):85-96. PMC: 6972638. DOI: 10.1111/bjd.18476. View

10.

Popovic B, Breed J, Rees D, Gardener M, Vinall L, Kemp B . Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2016; 429(2):208-219. DOI: 10.1016/j.jmb.2016.12.005. View

11.

Dhand A, Aminoff M . The neurology of itch. Brain. 2013; 137(Pt 2):313-22. DOI: 10.1093/brain/awt158. View

12.

Kamata M, Tada Y . A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. JID Innov. 2021; 1(3):100042. PMC: 8659403. DOI: 10.1016/j.xjidi.2021.100042. View

13.

Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C . Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013; 132(2):361-70. PMC: 3991240. DOI: 10.1016/j.jaci.2013.04.046. View

14.

Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T . Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2019; 145(1):215-228. PMC: 6957229. DOI: 10.1016/j.jaci.2019.09.031. View

15.

Blauvelt A, Guttman-Yassky E, Paller A, Simpson E, Cork M, Weisman J . Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022; 23(3):365-383. PMC: 9142443. DOI: 10.1007/s40257-022-00683-2. View

16.

Tran M, Lefebvre D, Dharma C, Dai D, Lou W, Subbarao P . Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2017; 141(2):601-607.e8. DOI: 10.1016/j.jaci.2017.08.024. View

17.

Cork M, McMichael A, Teng J, Valdez H, Rojo R, Chan G . Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes. J Eur Acad Dermatol Venereol. 2021; 36(3):422-433. PMC: 9299698. DOI: 10.1111/jdv.17792. View

18.

Bieber T, Thyssen J, Reich K, Simpson E, Katoh N, Torrelo A . Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2020; 35(2):476-485. DOI: 10.1111/jdv.16948. View

19.

Simpson E, Paller A, Siegfried E, Boguniewicz M, Sher L, Gooderham M . Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019; 156(1):44-56. PMC: 6865265. DOI: 10.1001/jamadermatol.2019.3336. View

20.

Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T . Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 2013; 68(4):498-506. PMC: 7159470. DOI: 10.1111/all.12112. View